@article{20a0380a3f6d4fec85d43d9ca35b45a3,
title = "A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis",
keywords = "Lactoferrin, Septic shock, Severe sepsis, Talactoferrin alfa",
author = "Kalpalatha Guntupalli and Nathan Dean and Morris, {Peter E.} and Venkata Bandi and Benjamin Margolis and Emanuel Rivers and Mitchell Levy and Lodato, {Robert F.} and Ismail, {Preeti M.} and Amber Reese and Schaumberg, {John P.} and Rajesh Malik and Dellinger, {R. Phillip}",
note = "Objectives Lactoferrin is a glycoprotein with anti-infective and anti-inflammatory properties found in secretions and immune cells. Talactoferrin alfa, a recombinant form of human lactoferrin, has similar properties and plays an important role in maintaining the gastrointestinal mucosal barrier integrity. In experimental animal models, administration of talactoferrin reduces translocation of bacteria from the gut into the systemic circulation and mortality from sepsis.",
year = "2013",
month = mar,
doi = "10.1097/CCM.0b013e3182741551",
language = "English",
volume = "41",
pages = "706--716",
journal = "Critical Care Medicine",
issn = "0090-3493",
number = "3",
}